Description

Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) 12%

Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) 12% (PHBV 12%) is a pharmaceutical-grade, biodegradable copolymer containing 12 mol% 3-Hydroxyvalerate (3HV). This controlled composition provides a balance of mechanical flexibility, processing performance, and customized biodegradation suitable for advanced drug delivery systems, implantable medical devices, and tissue engineering scaffolds.

• It is a pharmaceutical-grade polyhydroxyalkanoate (PHA) copolymer with 12 mol% 3HV
• It features tuned mechanical properties and extended degradation profile
• It enables controlled-release injectables, microspheres, implants, and scaffolds
• It is fully biocompatible with hydrolytic degradation into non-toxic metabolites

The 12% Hydroxyvalerate content in PHBV 12% enhances polymer elasticity, lowers crystallinity, and modulates degradation rates compared to pure Poly(3-hydroxybutyrate) (PHB). This composition is optimized for long-acting injectables and biodegradable implant platforms that require extended drug release profiles and tailored mechanical strength.

PHBV 12% supports advanced sustained-release formulations for parenteral injectables, drug-eluting stents, and implantable drug reservoirs. Its tunable degradation minimizes burst release, maintains consistent drug delivery, and eliminates the need for implant retrieval. In tissue engineering and regenerative medicine, PHBV 12% enables bioresorbable scaffolds, sutures, and wound-healing matrices that integrate with host tissue during biodegradation.

Pharmaceutical developers, formulation scientists, and device manufacturers seeking to purchase Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) 12% benefit from CarboMer’s highly controlled production processes, validated analytical methods, and full regulatory support for global compliance.

Material is packaged in tamper-evident containers to ensure long-term stability during storage and transportation. Minimum order quantities (MOQ), lead times, and comprehensive technical packages are available to support clinical and commercial programs.

Each batch undergoes analytical testing for molecular weight distribution, 3HV content (12 mol%) and other polymer properties. CarboMer’s manufacturing platform ensures reproducibility, regulatory alignment, and global supply assurance.

As with all CarboMer biomaterials, Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) 12% is supported by full technical consultation, formulation guidance, and regulatory expertise to help clients accelerate development and achieve global regulatory approvals efficiently.